The new company site http://www.uluruinc.com/

Lets see ULUR rock!

*** NEWS ***
http://biz.yahoo.com/prnews/060405/daw033.html?.v=50

Oxford Ventures Announces Completion of Merger With ULURU
Wednesday April 5, 8:00 am ET
- Name Change to ULURU Inc.
- Symbol Change on the OTC Bulletin Board: ULUR
- Implementation of Reverse Stock Split


DALLAS, April 5 /PRNewswire-FirstCall/ -- Oxford Ventures, Inc. (OTC Bulletin Board: OXFV - News; "OXFORD") today announced that its merger with ULURU, Inc. ("ULURU") has been completed. Under the terms of the merger agreement, ULURU has been merged into a subsidiary of Oxford, with Oxford being the surviving legal entity. Oxford has acquired all of the outstanding shares of ULURU in exchange for unregistered common stock of Oxford.
Oxford's name has been changed to ULURU Inc. and the new company headquarters are located at 4452 Beltway Drive, Addison, Texas, 75001.

Mr. Kerry P. Gray will be President and C.E.O. of ULURU. Additionally, Mr. Gray will serve on the Board of Directors along with:


Mr. William W. Crouse, Chairman
Mr. Jeffery B. Davis
Dr. David E. Reese

Effective April 5, 2006 the trading symbol on the OTC Bulletin Board will change from OXFV to ULUR. Additionally, the company has implemented a 1-for-400 reverse stock split. The reverse stock split will take effect and the shares will begin trading on a post-split basis at the opening of business on Wednesday, April 5, 2006.

With the completion of the merger and the reverse stock split the company will have approximately 13 million common shares outstanding. Shareholders will be notified by Continental Stock Transfer & Trust Company, ULURU's stock transfer agent, regarding the process for receiving new share certificates.

ULURU's business plan is to establish a market leadership position in the development of wound management, plastic surgery and oral care products utilizing innovative drug delivery solutions to improve clinical outcomes for patients and provide an economic benefit to healthcare providers. The company intends to establish a sales and marketing organization to market our product developments to the wound management and plastic surgery markets and to form strategic partnerships to market our range of oral products and other product developments that require a large sales organization. Acquiring and licensing products for wound management and plastic surgery is an integral component of our strategy of rapidly building a sales and marketing organization.

Commenting on the recent developments, Kerry P. Gray, President and C.E.O. of ULURU, stated, "With the completion of the merger and the appointment of a highly qualified Board of Directors, I look forward with excitement to building a leading company in the wound management, plastic surgery and oral care markets. We are very pleased with our progress in developing products from our technology platforms. Over the upcoming 12 months we expect three additional products to be marketed."

Mr. Gray continued, "The reverse split brings the number of shares outstanding and the share price more in line with companies of our size and stage of development. This is the first step to achieve our ultimate objective of applying for a listing on NASDAQ or an exchange."

ULURU Inc. is an emerging specialty pharmaceutical company focused on the development of a portfolio of wound management, plastic surgery and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative transmucosal delivery system and Hydrogel Nanoparticle Aggregate technology.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks, and uncertainties, including but not limited to statements made relating to the establishment of a sales and marketing organization, the marketing of three additional products and the achievement of a listing on NASDAQ or an exchange. These statements are subject to numerous risks, including but not limited to the risks detailed in the Company's Annual Report on Form 10-K, for the year ended December 31, 2004, Quarterly Report on Form 10-Q for the quarter ended September 30, 2005 and other reports filed by us with the Securities and Exchange Commission.


Contact Company
Kerry P. Gray
President and CEO

Terry K. Wallberg
Chief Financial Officer
(214) 905-5145

Looks like symbol has changed today to ULUR.OB.

13:25 04/05/2006 OXFV Oxford Ventures, Inc. Common Stock ULUR Uluru Inc. Common Stock 1-400 R/S **

April 3, 2006 PR:
http://biz.yahoo.com/e/060403/oxfv.ob8-k.html

A couple of them were frozen, the ones I added should self update.

OXFV / 3 Charts

nice charts on OXFV

Still watching here, just waiting for the company to do it's
shuffling,

Seen many post r.s. take off

M.G., of OXFV, has the goods, looking for news on the SBIR II update.

Holding my shares for the Fall 2006 launch

FYI: Just spoke with E*Trade. OXFV currently going thru reverse split ( 1 for 400 ) and is therefore halted. Was not able to tell me when trading would resume. I know that this is the second day of the halt. GLTA!

More exposure:
http://dallas.dbusinessnews.com/shownews.php?newsid=61820&type_news=past

ULURU Advances Development of Wound Management Portfolio; Initial Product Scheduled for Market Launch in the 4th Quarter

DALLAS -- ULURU INC. ("ULURU") who has signed a definitive merger agreement with Oxford Ventures, Inc. (OTC Bulletin Board: OXFV) today announced plans to launch its first wound management product utilizing its hydrogel nanoparticle aggregate technology onto the United States market in the fourth quarter, 2006.

In conjunction with the University of Texas Southwestern Medical Center ("UTSW"), we have conducted extensive preclinical studies on the biocompatibility of the hydrogel nanoparticle aggregate material and its effectiveness in wound healing. The results achieved to date indicate that the material is very biocompatible, does not elicit a foreign body response and when compared with a commercially available wound dressing significantly enhances healing.

Commenting on the results achieved in the UTSW preclinical models Dr. Spencer A. Brown, Director of Plastic Surgery Research Nancy L. and Perry Bass Advanced Wound Healing Laboratory at UTSW stated, "This material has produced unexpectedly superior results acting as both a protective barrier and producing a moist environment to accelerate wound healing. Positive results with the ULURU material were achieved with only one application in a 21 day study, while competitive products require multiple dressing changes during the same period. Reducing the number of dressing changes would not only be a significant savings to the health care provider but also improve the quality of life of the patient."

Currently the company is engaging contract manufacturers to produce the product for clinical studies and the subsequent commercial launch. ULURU plans to conduct phase IV clinical studies to support marketing of the material as a treatment of chronic wounds and burns.

Commenting on the strategic direction of ULURU, Kerry P. Gray, President and CEO of ULURU stated, "As we have previously outlined, it is our objective to establish a sales and marketing organization to market wound management and burn care products. It is planned to have in place, through the acquisition and licensing of complimentary products with established sales and marketing groups, the commercial organization to introduce this product in the fourth quarter. Given the preclinical profile of the Hydrogel Nanoparticle Aggregate material, we believe there is an exciting market opportunity for a range of wound management products utilizing this technology."

ULURU Inc. is an emerging specialty pharmaceutical company focused on the development of a portfolio of wound management, plastic surgery and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative transmucosal delivery system and Hydrogel Nanoparticle Aggregate technology.

hurley, you have a PM. eom

Minddoc7, this is, what seems to be, "break-through technology," Kerry Gray should
put this tid bit in the USA Today newspaper
and or, the Investors Business Daily,

Buy an ad.

If he is curious as to what it costs, maybe he can call ceo Scott Sands from IGTG,
and also there is the American Scene radio station that address stocks on the Money Channel.

USXP put a tid bit last week in USA newspaper and the pps went from .0004 to .007 to .008 area, from the exposure

20x

quote from today's news

Positive results with the ULURU material were achieved with only one application in a 21 day study, while competitive products require multiple dressing changes during the same period.

Same *NEWS* but in independent publication:
http://www.genengnews.com/news/bnitem.aspx?name=1167737XSL_NEWSML_TO_NEWSML.xml


ULURU Advances Development of Wound Management Portfolio; Initial Product Scheduled for Market Launch in the 4th Quarter
2/13/2006 10:16:00 AM EST

ULURU INC. ("ULURU") who has signed a definitive merger agreement with Oxford Ventures, Inc. (OTC Bulletin Board: OXFV) today announced plans to launch its first wound management product utilizing its hydrogel nanoparticle aggregate technology onto the United States market in the fourth quarter, 2006.

In conjunction with the University of Texas Southwestern Medical Center ("UTSW"), we have conducted extensive preclinical studies on the biocompatibility of the hydrogel nanoparticle aggregate material and its effectiveness in wound healing. The results achieved to date indicate that the material is very biocompatible, does not elicit a foreign body response and when compared with a commercially available wound dressing significantly enhances healing.

Commenting on the results achieved in the UTSW preclinical models Dr. Spencer A. Brown, Director of Plastic Surgery Research Nancy L. and Perry Bass Advanced Wound Healing Laboratory at UTSW stated, "This material has produced unexpectedly superior results acting as both a protective barrier and producing a moist environment to accelerate wound healing. Positive results with the ULURU material were achieved with only one application in a 21 day study, while competitive products require multiple dressing changes during the same period. Reducing the number of dressing changes would not only be a significant savings to the health care provider but also improve the quality of life of the patient."

Currently the company is engaging contract manufacturers to produce the product for clinical studies and the subsequent commercial launch. ULURU plans to conduct phase IV clinical studies to support marketing of the material as a treatment of chronic wounds and burns.

Commenting on the strategic direction of ULURU, Kerry P. Gray, President and CEO of ULURU stated, "As we have previously outlined, it is our objective to establish a sales and marketing organization to market wound management and burn care products. It is planned to have in place, through the acquisition and licensing of complimentary products with established sales and marketing groups, the commercial organization to introduce this product in the fourth quarter. Given the preclinical profile of the Hydrogel Nanoparticle Aggregate material, we believe there is an exciting market opportunity for a range of wound management products utilizing this technology."

News out.

February 13, 2006 - 10:16 AM EST

close Email this News Article
Your Name
Your Email
Friend's Name
Friend's Email
Receive Copy: yes

OXFV 0.0047 0.0004

Today 5d 1m 3m 1y 5y 10y



ULURU Advances Development of Wound Management Portfolio; Initial Product Scheduled for Market Launch in the 4th Quarter
ULURU INC. ("ULURU") who has signed a definitive merger agreement with Oxford Ventures, Inc. (OTC Bulletin Board: OXFV) today announced plans to launch its first wound management product utilizing its hydrogel nanoparticle aggregate technology onto the United States market in the fourth quarter, 2006.

In conjunction with the University of Texas Southwestern Medical Center ("UTSW"), we have conducted extensive preclinical studies on the biocompatibility of the hydrogel nanoparticle aggregate material and its effectiveness in wound healing. The results achieved to date indicate that the material is very biocompatible, does not elicit a foreign body response and when compared with a commercially available wound dressing significantly enhances healing.

Commenting on the results achieved in the UTSW preclinical models Dr. Spencer A. Brown, Director of Plastic Surgery Research Nancy L. and Perry Bass Advanced Wound Healing Laboratory at UTSW stated, "This material has produced unexpectedly superior results acting as both a protective barrier and producing a moist environment to accelerate wound healing. Positive results with the ULURU material were achieved with only one application in a 21 day study, while competitive products require multiple dressing changes during the same period. Reducing the number of dressing changes would not only be a significant savings to the health care provider but also improve the quality of life of the patient."

Currently the company is engaging contract manufacturers to produce the product for clinical studies and the subsequent commercial launch. ULURU plans to conduct phase IV clinical studies to support marketing of the material as a treatment of chronic wounds and burns.

Commenting on the strategic direction of ULURU, Kerry P. Gray, President and CEO of ULURU stated, "As we have previously outlined, it is our objective to establish a sales and marketing organization to market wound management and burn care products. It is planned to have in place, through the acquisition and licensing of complimentary products with established sales and marketing groups, the commercial organization to introduce this product in the fourth quarter. Given the preclinical profile of the Hydrogel Nanoparticle Aggregate material, we believe there is an exciting market opportunity for a range of wound management products utilizing this technology."

ULURU Inc. is an emerging specialty pharmaceutical company focused on the development of a portfolio of wound management, plastic surgery and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative transmucosal delivery system and Hydrogel Nanoparticle Aggregate technology.


ULURU INC.
Kerry P. Gray, 214-905-5145



Source: Business Wire (February 13, 2006 - 10:16 AM EST)

News by QuoteMedia
www.quotemedia.com

Okay, I'll live with the quiet as long as the pps continues to increase.

Much too quiet here!eom

Jrod ,
Looks like OXFV is getting ready for another run up..10 day ,30min chart shows the 40 day ma is just crossing over the 20ma..and the macd is showing a buy.........any thoughts?
Don

Nice, another 2% pps increase today. GLTA!!!

What I am looking at on OXFV is the breakout of the top trend line confirmed by the bullish indicators (on the chart with T/A).

The EMA 200 is the next resistance I see and I have this as a target to take profits as I always take profits at percieved resistance points.

The EMA 200 is near .0075 but I will have a better view as it gets closer.

This could be the start of a longer term trend IMO so I will still hold a small core of shares that I can work with in the future, in the case that the PPS (price per share) crosses above this EMA 200 Resistance I will still be riding shares and visa versa, if it does not cross I will have taken profits anyway.

On the Weekly Chart:
This is a longer duration chart and suggests that the PPS may be entering a longer trend. As always, the MAs (support/resistance) will tell the tale.

OXFV / 4 Charts.....

Again a 6% pps increase. Interesting.

OXFV

Today, yet another 6% pps increase. Slow and steady progress. OXFV behaving like a Big Boy stock. Nice to see. GLTA!!!

JROD........you're awesome..........thank you so much. RI

Not a pest Rook. I dont mind at all. The RSI 14 is the default on most charts/services. By "default" this makes the "14" the most commonly used duration by chartists and all who read charts.

You can think of it as a "self fulfilling prophecy" as many people will trade by these indicators which increases their relevance.

Remember that all indicators can be adjusted to fit time frames, strategies etc...

I learned to use the RSI (2) as a "Swing" indicator of strength, "today as compared to the day before". It is strictly used for short term "swing" and momentum trades.

The RSI (14) is used more in confirmation of the medium term "trend" using the MA50.

Both display strength of the "trend"(14) or "swing"(2) as well as gives clues to top/bottom reversals, IMO.

See this link to "stockcharts" RSI page....
http://stockcharts.com/education/IndicatorAnalysis/indic_RSI.html

JROD....if you're around today. Another question. Hope, I'm not a pest. I totally understand RSI and Wms%, at least the concept. However when you factor RSI2 or RSI7 or 14......that kind of throws me off........It seems like when you check a chart ( like on stockcharts ) 14 is the default.......Is 14 a common indicator and more stable.......as opposed to RSI2 that is a quicker indicator.........????? THANKS.....still can't afford the premium, but you see I'm workin' on it......

rookinvestor

Oh now that is a pretty chart.
I love the psychology of charts.
Look how former bagholders got out after the spike...
Then look how many are slowly getting back in as they see potential.
I'm not big on popular indicators as I find they rarely tell me anything I don't already know.
What I do watch is price formations and trends.
I like how the price is slowly and smoothly curving north.

Thank you, and good luck to you as well. -e-

JROD........as always YOU'RE awesome!!. Thank you very much. That was a very clear explanation. You have a very nice board.......Good Luck....................


I'm still a rook!

Sure Rook. The RSI can be thought of as "relative strength". In other words the RSI 2 would indicate todays strength as compared to yesterdays strength. On the same note, The RSI 14 would indicate todays strength as compared to the last 14 days. I use the RSI 2 for watching strength in the short price swings. I use the RSI 14 to watch the strength in the longer "trends".

Hope this helps.....

JROD.....I'm still a poor rookie trader. But I'm a learning fool. I can't afford the premium so I can only read your board and not post. Can you explain the basic difference between RSI 2 and RSI 14.............I was reading and studying your T/A but don't quite understand the difference??

Thanks............nice board...............rookinvestor

OXFV / Weekly Chart....

chart on OXFV, macd is North and moving

Very few stocks were green in my portfolio today but, OXFV was one of them. Closed at high for the day. Seems to be holding and growing. GLTA!!!

Mindoc, seems that last
fat finger trade was corrected in the charts

weekly bollies still looking good

daily bolllies need some some viagra from
KG

need news

obviously the fire is being fed of some sort, but KG needs to put out some goods

em

Kerry Gray, put out some news! ULURU

Me too, OXFV seems to be basing in the mid .004's, em

PPS holding recent gains well. Will watch to see how we end the week. GLTA!!!

So what's going on here?

This stock has quietly and slowly gone from the low .003s to the high .004s, an almost 50% increase up to the levels immediately following the 12/6/05 PR, which was the company's biggest acheivement to date and a far more important development than the SBIR grant.

Is this share related (RS, rumors i've heard of reducing the Auth. shares), in which case the gain probably is temporary.

Or are they making headway on the commercial launch of OraDisc? They already know aphthasol doesn't sell by itself, too much of a pain for patients to use, and the FDA gave Oradisc the clear almost a year ago. This should be, and looks like it is, the number one priority for this company.

I do wish they would provide more details and perhaps a timeline on that, but it's an OTC stock, i'm not holding my breath.

Tried to pick up more today @.0044, but only got a partial fill. And they were not easy to get! I suspect the low float combined with shares being held, are going to make it even more difficult to buy in the short term. GLTA!!!

OXFV to AMEX?

Whoa, I guess we had a fat finger for that 0.044! Things to come?

After following OXFV for a while, you guys and gals might want to take a look at AVST, which imo has the same thing going for it right now in terms of a merger etc. (before the price explosion to .01 like OXFV)

Check the AVST iHub board for details.

minddoc7, was just pointed out to the OXFV weekly chart

setting up nice, bollies coming together

Setting up nicely. Looking for a run in the near term. GLTA!!!

Good morning. Any news on a r/s for the shares?
SN

OXFV chart, cmf postive, macd break out, YE HAAAAAHHHHHH :)

Some increased volume resulting in a nice move today.

OXFV, this is the next step

OXFV, chart with some links


http://www.aro.army.mil/arowash/rt/commercialization/comm.htm

Just to know, the previous info can be found at

http://www.investorshub.com/boards/read_msg.asp?Message_id=8324269&txt2find=oxfv

and, or

http://www.investorshub.com/boards/read_msg.asp?Message_id=8334962&txt2find=oxfv